Abstract
Amaç: Çalışmamızda polikliniğimize başvuran
hastalar arasında trombositoz sıklığını ve nedenlerini araştırmayı planladık. Yöntem: Mayıs 2014-Mayıs 2015 tarihleri
arasında Mersin Üniversitesi Tıp Fakültesi Çocuk Hematoloji BD’na başvuran,
3400 hastanın laboratuar parametreleri incelendi. Bu inceleme sırasında
trombositozu olan 319 (%11.0) hasta saptandı ve bu hastaların yaş, cinsiyet,
laboratuar parametreleri (hemoglobin, beyaz küre, trombositler) ve tanıları
dosyalarından kaydedildi. Bulgular: Çalışmanın konusunu oluşturan 319 trombositozlu hastanın
197’si (%61.8) erkek, 122’si (% 38.2) kız, yaşları ortalama 72.0±69.0 (1-216
ay) aydı. Hastalarımızın ortalama trombosit sayısı 596 430±286 120/μL (450
000-1 523 000) olarak bulundu. Hastaların hepsinde sekonder trombositoz
mevcutken en sık neden %37.9 ile enfeksiyonlardı. Diğer sık nedenler arasında
orak hücre anemisi (%21.2), demir eksikliği anemisi (%15.4), kollojen doku
hastalıkları (%6.6), hemolitik anemiler (%5.0), splenektomi (%4.4) ve diğer
nedenler (%9.7) olarak belirlendi. Tartışma:
Çalışmamızda en sık trombositoz nedeni, literatürle uyumlu olarak
enfeksiyonlara bağlı bulurken, demir eksikliği ve orak hücreli anemi sekonder
trombositozun diğer sık nedenleri arasında yer aldı. Bölgemizde demir eksikliği anemisinin %70-80
gibi çok yüksek oranlarda olması nedeniyle, bu yüksek oranları görmüş
olabileceğimiz ve bölgesel farklılıklara bağlı olarak orak hücreli anemi gibi
hemolitik anemilerin de ayırıcı tanıda akılda tutulması gerektiğini
düşünmekteyiz.
Keywords
References
- 1. Dame C, Sutor A H. Primary and secondary thrombocytosis in childhood. Br J Haematol.2005;129:165–177.
- 2. Vafaie M, Jaseb K, Ghanavat M, Pedram M, Rahiminia T. Asymtomatic Essential Thrombocythemia in a Child: A Rare Case Report. Int J Hematol Oncol Stem Cell Res. 2013; 7 (2): 35–37.
- 3.Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994; 77:1117-24.
- 4. Matsubara K, Fukaya T, Nigami H et al. Age-dependent changes in the incidence and etiology of childhood thrombocytosis. Acta Haematol 2004; 111:132-7
- 5. Sola MC, Du Y, Hutson AD, Christensen RD. Doseresponse relationship of megakaryocyte progenitors from the bone marrow of thrombocytopenic and non-thrombocytopenic neonates to recombinant thrombopoietin. Br J Haematol 2000; 110:449-53.
- 6. Ishiguro A, Ishikita T, Shimbo T, et al. Elevation of serum thrombopoietin precedes thrombocytosis in Kawasaki disease. Thromb Haemost 1998;79:1096–1100.
- 7. Barton BE. The biological effects of interleukin 6. Med Res Rev 1996;16:87- 109.
- 8. Takagi M, Egawa T, Motomura T, et al. Interleukin-6 secreting phaeochromocytoma associated with clinical markers of inflammation. Clin Endocrinol 1997;46:507–509.
- 9. Hirano T, A.S, Taga T, et al., Biological and clinical aspects of interleukin 6. Immunol Today, 1990. 11: p. 443-449.
- 10. Wolber EM, Jelkmann W. Interleukin-6 increases thrombopoietin production in human hepatoma cells HepG2 and Hep3B. J Interferon Cytokine Res 2000; 20: 499-506. 117
- 11. Unsal E, Aksaray S, Köksal D, Sipit T. Potential role of interleukin 6 in reactive thrombocytosis and acute phase response in pulmonary tuberculosis. Postgrad Med J. 2005; 81:604–607.
- 12. Tefferi A, Ho TC, Ahmann GJ, Katzmann JA, Greipp PR SO. Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. Am J Med. 1994;97 (4):374.
- 13. Komura E, Matsumura T, Kato T, Tahara T, Tsunoda Y, Sawada T. Thrombopoietin in patients with hepatoblastoma. Stem Cells 1998; 16:329- 33.
- 14. Sasaki Y, Takahashi T, Miyazaki H et al. Production of thrombopoietin by human carcinomas and its novel isoforms. Blood 1999; 94:1952-60.
- 15. Blatt J, Penchansky L, Horn M. Thrombocytosis as a presenting feature of acute lymphoblastic leukemia in childhood. Am J Hematol 1989; 31:46-9.
- 16. Dame C, Sutor A H. Primary and secondary thrombocytosis in childhood. Br J Haematol.2005;129:165–177.
- 17. Giona F, Teofili L, Moleti ML, Martini M, Palumbo G, Amendola A, et al. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood. 2012;119 (10):2219–27.
- 18. Van Genderen PJ, Michiels JJ. Primary thrombocythemia: diagnosis, clinical manifestations and management. Ann Hematol 1993;67:57.
- 19. Schafer AI. Thrombocytosis. N Eng J Med 2004; 350:1211-19
- 20. Dua V, Yadav SP, Kumar V, Saxena R, Sachdeva A. Two cases of pediatric essential thrombocythemia managed effectively with hydroxyurea. Int J Hematol. 2012; 96 (6):810-3.
- 21. Randi ML, Putti MC. Essential thrombocythaemia in children: is a treatment needed? Expert Opin Pharmacother 2004; 5:1009-14.
- 22. Van Genderen PJJ, Mulder PGH, Waleboer M et al. Prevention and treatment of thrombotic complications in essential thrombocythemia: efficacy and safety of aspirin. Br J Haematol 1997; 97: 179).
- 23. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001; 97:863-6.
- 24. Sutor AH. Thrombocytosis in childhood. Semin Thromb Hemost 1995; 21:330-9.)
- 25. Sutor AH. Screening children with thrombosis for thrombophilic proteins.Cui bono? J Thromb Haemost 2003;1;886-8.
- 26. Matsubara K, Fukaya T, Nigami H, et al. Age-dependent changes in the incidence and etiology of childhood thrombocytosis. Acta Haematologica. 2004;111 (3):132–137.
- 27.Subramaniam N, Mundkur S, Kini P, Bhaskaranand N, Aroor S. Clinicohematological study of thrombocytosis in children. ISRN Hematol. 2014; 2014:389257
- 28. Chen H.L, Chiou S.S, Sheen J.M, Jang R.C, Lu C.C, Chang T.T. Thrombocytosis in children at one medical center of southern Taiwan. Acta Paediatr Taiwan 1999; 40, 309–313.
- 29. Sutor A.H, Hank D. Thrombosen bei Thrombozytosen im Kindesalter. In: Thrombosen im Kindesalter. Risikofaktoren - Diagnose - Prophylaxe - Therapie (ed. by A.H.Sutor), 1992;. 113–136. Roche, Basel.
- 30. Vora AJ, Lilleyman JS. Secondary thrombocytosis. Arch Dis Child 1993; 68:88-90.
- 31. Yohannan, M.D, Higgy, K.E, al-Mashhadani, S.A. & Santhosh-Kumar, C.R.Thrombocytosis. Etiologic analysis of 663 patients. Clin Pediatr. 1994;33(6):340-3.
- 32. Özcan C, Şaylı TR, Koşan-Çulha V. Reactive thrombocytosis in children. Turk J Pediatr. 2013;55 (4):411-6.
- 33. Subramaniam N, Mundkur S, Kini P, Bhaskaranand N, Aroor S. Clinicohematological study of thrombocytosis in children. ISRN Hematol. 2014; 2014:389257.
- 34. Dahmani F, Benkirane S, Kouzih J, Woumki A, Mamad H, Masrar A. Evaluation of hemogram in patients with homozygous sickle cell disease: about 87 cases. Pan Afr Med J. 2016; 25: 240.
Abstract
References
- 1. Dame C, Sutor A H. Primary and secondary thrombocytosis in childhood. Br J Haematol.2005;129:165–177.
- 2. Vafaie M, Jaseb K, Ghanavat M, Pedram M, Rahiminia T. Asymtomatic Essential Thrombocythemia in a Child: A Rare Case Report. Int J Hematol Oncol Stem Cell Res. 2013; 7 (2): 35–37.
- 3.Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994; 77:1117-24.
- 4. Matsubara K, Fukaya T, Nigami H et al. Age-dependent changes in the incidence and etiology of childhood thrombocytosis. Acta Haematol 2004; 111:132-7
- 5. Sola MC, Du Y, Hutson AD, Christensen RD. Doseresponse relationship of megakaryocyte progenitors from the bone marrow of thrombocytopenic and non-thrombocytopenic neonates to recombinant thrombopoietin. Br J Haematol 2000; 110:449-53.
- 6. Ishiguro A, Ishikita T, Shimbo T, et al. Elevation of serum thrombopoietin precedes thrombocytosis in Kawasaki disease. Thromb Haemost 1998;79:1096–1100.
- 7. Barton BE. The biological effects of interleukin 6. Med Res Rev 1996;16:87- 109.
- 8. Takagi M, Egawa T, Motomura T, et al. Interleukin-6 secreting phaeochromocytoma associated with clinical markers of inflammation. Clin Endocrinol 1997;46:507–509.
- 9. Hirano T, A.S, Taga T, et al., Biological and clinical aspects of interleukin 6. Immunol Today, 1990. 11: p. 443-449.
- 10. Wolber EM, Jelkmann W. Interleukin-6 increases thrombopoietin production in human hepatoma cells HepG2 and Hep3B. J Interferon Cytokine Res 2000; 20: 499-506. 117
- 11. Unsal E, Aksaray S, Köksal D, Sipit T. Potential role of interleukin 6 in reactive thrombocytosis and acute phase response in pulmonary tuberculosis. Postgrad Med J. 2005; 81:604–607.
- 12. Tefferi A, Ho TC, Ahmann GJ, Katzmann JA, Greipp PR SO. Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. Am J Med. 1994;97 (4):374.
- 13. Komura E, Matsumura T, Kato T, Tahara T, Tsunoda Y, Sawada T. Thrombopoietin in patients with hepatoblastoma. Stem Cells 1998; 16:329- 33.
- 14. Sasaki Y, Takahashi T, Miyazaki H et al. Production of thrombopoietin by human carcinomas and its novel isoforms. Blood 1999; 94:1952-60.
- 15. Blatt J, Penchansky L, Horn M. Thrombocytosis as a presenting feature of acute lymphoblastic leukemia in childhood. Am J Hematol 1989; 31:46-9.
- 16. Dame C, Sutor A H. Primary and secondary thrombocytosis in childhood. Br J Haematol.2005;129:165–177.
- 17. Giona F, Teofili L, Moleti ML, Martini M, Palumbo G, Amendola A, et al. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood. 2012;119 (10):2219–27.
- 18. Van Genderen PJ, Michiels JJ. Primary thrombocythemia: diagnosis, clinical manifestations and management. Ann Hematol 1993;67:57.
- 19. Schafer AI. Thrombocytosis. N Eng J Med 2004; 350:1211-19
- 20. Dua V, Yadav SP, Kumar V, Saxena R, Sachdeva A. Two cases of pediatric essential thrombocythemia managed effectively with hydroxyurea. Int J Hematol. 2012; 96 (6):810-3.
- 21. Randi ML, Putti MC. Essential thrombocythaemia in children: is a treatment needed? Expert Opin Pharmacother 2004; 5:1009-14.
- 22. Van Genderen PJJ, Mulder PGH, Waleboer M et al. Prevention and treatment of thrombotic complications in essential thrombocythemia: efficacy and safety of aspirin. Br J Haematol 1997; 97: 179).
- 23. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001; 97:863-6.
- 24. Sutor AH. Thrombocytosis in childhood. Semin Thromb Hemost 1995; 21:330-9.)
- 25. Sutor AH. Screening children with thrombosis for thrombophilic proteins.Cui bono? J Thromb Haemost 2003;1;886-8.
- 26. Matsubara K, Fukaya T, Nigami H, et al. Age-dependent changes in the incidence and etiology of childhood thrombocytosis. Acta Haematologica. 2004;111 (3):132–137.
- 27.Subramaniam N, Mundkur S, Kini P, Bhaskaranand N, Aroor S. Clinicohematological study of thrombocytosis in children. ISRN Hematol. 2014; 2014:389257
- 28. Chen H.L, Chiou S.S, Sheen J.M, Jang R.C, Lu C.C, Chang T.T. Thrombocytosis in children at one medical center of southern Taiwan. Acta Paediatr Taiwan 1999; 40, 309–313.
- 29. Sutor A.H, Hank D. Thrombosen bei Thrombozytosen im Kindesalter. In: Thrombosen im Kindesalter. Risikofaktoren - Diagnose - Prophylaxe - Therapie (ed. by A.H.Sutor), 1992;. 113–136. Roche, Basel.
- 30. Vora AJ, Lilleyman JS. Secondary thrombocytosis. Arch Dis Child 1993; 68:88-90.
- 31. Yohannan, M.D, Higgy, K.E, al-Mashhadani, S.A. & Santhosh-Kumar, C.R.Thrombocytosis. Etiologic analysis of 663 patients. Clin Pediatr. 1994;33(6):340-3.
- 32. Özcan C, Şaylı TR, Koşan-Çulha V. Reactive thrombocytosis in children. Turk J Pediatr. 2013;55 (4):411-6.
- 33. Subramaniam N, Mundkur S, Kini P, Bhaskaranand N, Aroor S. Clinicohematological study of thrombocytosis in children. ISRN Hematol. 2014; 2014:389257.
- 34. Dahmani F, Benkirane S, Kouzih J, Woumki A, Mamad H, Masrar A. Evaluation of hemogram in patients with homozygous sickle cell disease: about 87 cases. Pan Afr Med J. 2016; 25: 240.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Articles |
| Authors | |
| Publication Date | August 15, 2018 |
| Submission Date | June 7, 2018 |
| Acceptance Date | July 23, 2018 |
| Published in Issue | Year 2018 Volume: 11 Issue: 2 |
Cite
MEU Journal of Health Sciences Assoc was began to the publishing process in 2008 under the supervision of Assoc. Prof. Gönül Aslan, Editor-in-Chief, and affiliated to Mersin University Institute of Health Sciences. In March 2015, Prof. Dr. Caferi Tayyar Şaşmaz undertook the Editor-in Chief position and since then he has been in charge.
Publishing in three issues per year (April - August - December), it is a multisectoral refereed scientific journal. In addition to research articles, scientific articles such as reviews, case reports and letters to the editor are published in the journal. Our journal, which has been published via e-mail since its inception, has been published both online and in print. Following the Participation Agreement signed with TÜBİTAK-ULAKBİM Dergi Park in April 2015, it has started to accept and evaluate online publications.
Mersin University Journal of Health Sciences have been indexed by Turkey Citation Index since November 16, 2011.
Mersin University Journal of Health Sciences have been indexed by ULAKBIM Medical Database from the first issue of 2016.
Mersin University Journal of Health Sciences have been indexed by DOAJ since October 02, 2019.
Article Publishing Charge Policy: Our journal has adopted an open access policy and there is no fee for article application, evaluation, and publication in our journal. All the articles published in our journal can be accessed from the Archive free of charge.
This work is licensed with Attribution-NonCommercial 4.0 International.